ALT vs BIOA
ALT: A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets. BIOA: Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant NLRP3 inhibitor BGE-102.
Side-by-side fundamentals
| Metric | ALT | BIOA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.96 | $24.85 | |
| Market cap as of 2026-07-31 | $576M | $986M | |
| PEG as of 2026-07-31 | n/a | -0.50 | |
| Net margin as of 2026-07-31 | -214861.0% | -871.8% | BIOA higher |
| Gross margin as of 2026-07-31 | +100.5% | n/a | |
| Operating margin as of 2026-07-31 | -230461.0% | -985.9% | BIOA higher |
| ROE as of 2026-07-31 | -42.6% | -29.4% | BIOA higher |
| ROA as of 2026-07-31 | -35.6% | -27.3% | BIOA higher |
| Debt / equity as of 2026-07-31 | 0.12 | 0.00 | BIOA lower |
| Revenue growth (YoY) as of 2026-07-31 | +80.0% | +91.0% | BIOA higher |
| Beta as of 2026-07-31 | 0.14 | 0.96 | |
| 1-year return as of 2026-07-27 close | -27.5% | +462.2% | BIOA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.